Miltenyi Bioindustry is a global CDMO service provider specializing in cell and gene therapy. With more than 25 years of experience, we offer comprehensive process development and manufacturing services for both autologous and allogeneic cell therapy programs. We provide high-quality lentiviral...
Proprietary Platform Moves Promising Cell Therapy Candidates from Contract to Clinic in Six Months NEWARK, NJ, June 1, 2023 – BioCentriq®, a strategic CDMO (contract development and manufacturing organization) specializing in cell therapy launched their new LEAP Advanced Therapy...
Monday, January 9, 2023 (Toronto, ON) – Viral vectors are critical components in the manufacturing of cell and gene therapies, but their production is currently a key bottleneck and cost driver. CCRM, a leader in developing and commercializing cell and gene therapies, has partnered with Membio,...
Recently, Eutilex, a partner of GenScript ProBio, announced MFDS clearance of its hepatocellular carcinoma clinical trial application for innovative CAR-T program (EU307). GenScript ProBio extends congratulations on this. 2 years ago, GenScript ProBio and Eutilex announced that the parties...
Sponsored Article Provided by Thermo Fisher Thermo Fisher Scientific Patheon Translational Services facility in San Diego The advanced therapies field is expected to grow at an impressive pace even with the recent global macroeconomic and COVID-19 pandemic setbacks....
OmniaBio Expands Manufacturing Footprint with Second Hamilton Location January 24, 2023 (Hamilton, ON) – OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre (MUMC). The new facility is now...
MicrofluidX and CCRM Partner on End-to-End Bioprocessing of CAR-T Cell Therapies Stevenage, UK, and Toronto, Canada, January 11, 2023— MicrofluidX (MFX), a UK-based provider of next-generation bioreactors for cell research and manufacturing, today announced a partnership with CCRM , a...
BioCentriq, Inc.—a New Jersey-based, cell and gene therapy contract development and manufacturing organization (CDMO)—announced today that they've completed a study designed to test transfection of T-cells with GFP mRNA for evaluation of cell viability, transfection efficiency, and post...
Sponsored article provided by Santen Founded in Japan over a century ago, Santen has been contributing to people’s eye health for the past 130 years. During this time the company has expanded to over 60 countries, reaching the number 1 position in the Japanese and Chinese ophthalmic...
Members in the News: Minaris Regenerative Medicine Minaris Regenerative Medicine GmbH and Mendus AB extend manufacturing partnership to large-scale production of DCP-001, an experimental allogeneic cell-based immunotherapy addressing tumor recurrence Munich, Germany, and...